# **Patient baseline characteristics**

## Optum (keep all) / 1:100 variable ratio matching

### Users of abiraterone + prednisone with CRPC vs. Users of enzalutamide with CRPC

### Ischemic stroke

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Before matching |  | | After matching |  | |
|  | of abiraterone + prednisone with CRPC | Users of enzalutamide with CRPC |  | of abiraterone + prednisone with CRPC | Users of enzalutamide with CRPC |  |
| Characteristic | % | % | Std. diff | % | % | Std. diff |
| Age group |  |  |  |  |  |  |
| 45-49 | 0.3 | 0.2 | 0.01 | -0.2 | 0.3 | -0.03 |
| 50-54 | 1.1 | 0.8 | 0.03 | 1.0 | 0.9 | 0.01 |
| 55-59 | 3.6 | 2.7 | 0.05 | 4.0 | 2.7 | 0.07 |
| 60-64 | 6.8 | 6.5 | 0.01 | 6.9 | 6.6 | 0.01 |
| 65-69 | 11.5 | 12.0 | -0.01 | 11.2 | 12.9 | -0.05 |
| 70-74 | 20.0 | 19.9 | 0.00 | 21.0 | 21.0 | 0.00 |
| 75-79 | 20.3 | 20.9 | -0.02 | 20.3 | 20.6 | -0.01 |
| 80-84 | 19.3 | 18.6 | 0.02 | 18.3 | 18.0 | 0.01 |
| 85-89 | 16.2 | 17.5 | -0.03 | 16.2 | 16.1 | 0.00 |
| 90-94 | 0.8 | 0.8 | 0.00 | 0.9 | 0.6 | 0.03 |
| Medical history: General |  |  |  |  |  |  |
| Acute respiratory disease | 18.9 | 21.2 | -0.06 | 19.1 | 19.2 | 0.00 |
| Attention deficit hyperactivity disorder | 0.2 | 0.2 | -0.01 | 0.2 | 0.2 | 0.01 |
| Chronic liver disease | 2.6 | 2.6 | 0.00 | 2.8 | 2.7 | 0.00 |
| Chronic obstructive lung disease | 15.4 | 16.5 | -0.03 | 15.2 | 15.1 | 0.00 |
| Crohn's disease | 0.4 | 0.3 | 0.02 | 0.2 | 0.2 | 0.01 |
| Dementia | 3.8 | 4.4 | -0.03 | 3.4 | 3.2 | 0.01 |
| Depressive disorder | 11.5 | 12.6 | -0.03 | 11.0 | 11.4 | -0.01 |
| Diabetes mellitus | 30.8 | 34.6 | -0.08 | 32.7 | 31.1 | 0.03 |
| Gastroesophageal reflux disease | 11.6 | 13.6 | -0.06 | 11.8 | 12.8 | -0.03 |
| Gastrointestinal hemorrhage | 5.1 | 5.8 | -0.03 | 4.7 | 4.6 | 0.00 |
| Human immunodeficiency virus infection | 0.3 | 0.3 | 0.00 | 0.3 | 0.3 | 0.00 |
| Hyperlipidemia | 61.9 | 64.7 | -0.06 | 61.7 | 63.2 | -0.03 |
| Hypertensive disorder | 72.9 | 75.1 | -0.05 | 72.9 | 72.7 | 0.00 |
| Lesion of liver | 4.0 | 5.0 | -0.04 | 4.0 | 4.6 | -0.03 |
| Obesity | 10.3 | 12.3 | -0.06 | 11.1 | 11.9 | -0.02 |
| Osteoarthritis | 39.1 | 39.8 | -0.01 | 37.4 | 39.0 | -0.03 |
| Pneumonia | 7.4 | 9.5 | -0.07 | 7.5 | 7.6 | -0.01 |
| Psoriasis | 1.1 | 1.0 | 0.01 | 1.2 | 1.0 | 0.01 |
| Renal impairment | 27.6 | 30.0 | -0.05 | 27.9 | 26.6 | 0.03 |
| Rheumatoid arthritis | 1.0 | 1.0 | 0.00 | 1.0 | 0.8 | 0.02 |
| Schizophrenia | -0.1 | -0.1 | 0.01 | -0.2 | -0.1 | 0.01 |
| Ulcerative colitis | 0.5 | 0.6 | 0.00 | 0.6 | 0.4 | 0.02 |
| Urinary tract infectious disease | 20.4 | 22.9 | -0.06 | 19.2 | 19.2 | 0.00 |
| Viral hepatitis C | 0.6 | 0.6 | 0.00 | 0.5 | 0.5 | 0.00 |
| Visual system disorder | 45.5 | 47.1 | -0.03 | 46.1 | 46.9 | -0.02 |
| Medical history: Cardiovascular disease |  |  |  |  |  |  |
| Atrial fibrillation | 15.5 | 16.5 | -0.03 | 14.8 | 14.2 | 0.02 |
| Cerebrovascular disease | 7.4 | 8.0 | -0.02 | 5.3 | 6.1 | -0.04 |
| Coronary arteriosclerosis | 28.4 | 29.0 | -0.01 | 27.3 | 26.9 | 0.01 |
| Heart disease | 50.9 | 52.7 | -0.04 | 50.0 | 49.5 | 0.01 |
| Heart failure | 13.3 | 16.3 | -0.08 | 13.2 | 13.4 | -0.01 |
| Ischemic heart disease | 13.2 | 14.0 | -0.02 | 12.5 | 12.4 | 0.00 |
| Peripheral vascular disease | 36.0 | 36.9 | -0.02 | 34.2 | 34.4 | 0.00 |
| Pulmonary embolism | 2.7 | 2.9 | -0.01 | 2.5 | 2.3 | 0.01 |
| Venous thrombosis | 5.2 | 5.6 | -0.02 | 4.9 | 4.8 | 0.00 |
| Medical history: Neoplasms |  |  |  |  |  |  |
| Hematologic neoplasm | 20.3 | 20.7 | -0.01 | 18.8 | 20.7 | -0.05 |
| Malignant lymphoma | 1.7 | 1.7 | 0.00 | 1.6 | 1.7 | -0.01 |
| Malignant neoplasm of anorectum | 0.9 | 0.8 | 0.01 | 0.8 | 0.9 | -0.02 |
| Malignant neoplastic disease | 99.8 | 99.9 | -0.02 | 99.8 | 99.9 | -0.03 |
| Malignant tumor of breast | 0.5 | 0.6 | -0.01 | 0.5 | 0.5 | 0.00 |
| Malignant tumor of colon | 2.5 | 2.4 | 0.00 | 2.4 | 2.0 | 0.03 |
| Malignant tumor of lung | 5.5 | 5.0 | 0.02 | 5.4 | 4.6 | 0.04 |
| Malignant tumor of urinary bladder | 5.3 | 5.4 | 0.00 | 5.4 | 4.9 | 0.02 |
| Primary malignant neoplasm of prostate | 99.8 | 99.9 | -0.02 | 99.8 | 99.9 | -0.03 |
| Medication use |  |  |  |  |  |  |
| Agents acting on the renin-angiotensin system | 48.6 | 50.6 | -0.04 | 49.2 | 49.5 | -0.01 |
| Antibacterials for systemic use | 65.5 | 66.3 | -0.02 | 63.9 | 63.6 | 0.01 |
| Antidepressants | 21.3 | 22.7 | -0.03 | 21.1 | 21.3 | 0.00 |
| Antiepileptics | 16.3 | 16.7 | -0.01 | 16.1 | 15.6 | 0.01 |
| Antiinflammatory and antirheumatic products | 21.6 | 21.8 | -0.01 | 20.3 | 21.5 | -0.03 |
| Antineoplastic agents | 14.2 | 17.0 | -0.08 | 15.4 | 15.3 | 0.00 |
| Antipsoriatics | 1.1 | 1.2 | -0.01 | 1.1 | 0.9 | 0.02 |
| Antithrombotic agents | 29.1 | 28.7 | 0.01 | 27.3 | 25.7 | 0.04 |
| Beta blocking agents | 39.1 | 39.7 | -0.01 | 39.4 | 37.9 | 0.03 |
| Calcium channel blockers | 27.2 | 29.8 | -0.06 | 26.9 | 27.9 | -0.02 |
| Diuretics | 38.0 | 41.6 | -0.07 | 39.4 | 39.1 | 0.01 |
| Drugs for acid related disorders | 30.5 | 33.6 | -0.07 | 30.2 | 30.6 | -0.01 |
| Drugs for obstructive airway diseases | 21.2 | 22.7 | -0.04 | 21.0 | 21.9 | -0.02 |
| Drugs used in diabetes | 21.7 | 26.1 | -0.10 | 23.7 | 23.1 | 0.01 |
| Immunosuppressants | 1.5 | 1.6 | -0.01 | 1.9 | 1.5 | 0.03 |
| Lipid modifying agents | 52.8 | 54.1 | -0.03 | 52.9 | 52.7 | 0.00 |
| Opioids | 43.6 | 43.6 | 0.00 | 42.5 | 40.7 | 0.04 |
| Psycholeptics | 33.6 | 34.4 | -0.02 | 33.4 | 32.8 | 0.01 |
| Psychostimulants, agents used for adhd and nootropics | 1.5 | 1.5 | 0.00 | 1.6 | 1.2 | 0.03 |

## Optum (keep all) / 1:100 variable ratio matching

### Users of abiraterone + prednisone with CRPC vs. Users of enzalutamide with CRPC

### Heart failure

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Before matching |  | | After matching |  | |
|  | of abiraterone + prednisone with CRPC | Users of enzalutamide with CRPC |  | of abiraterone + prednisone with CRPC | Users of enzalutamide with CRPC |  |
| Characteristic | % | % | Std. diff | % | % | Std. diff |
| Age group |  |  |  |  |  |  |
| 45-49 | 0.3 | 0.2 | 0.01 | -0.2 | 0.3 | -0.03 |
| 50-54 | 1.1 | 0.8 | 0.03 | 1.1 | 1.0 | 0.01 |
| 55-59 | 3.6 | 2.7 | 0.05 | 4.2 | 2.9 | 0.07 |
| 60-64 | 6.8 | 6.5 | 0.01 | 7.3 | 6.7 | 0.02 |
| 65-69 | 11.5 | 12.0 | -0.01 | 11.6 | 13.0 | -0.04 |
| 70-74 | 20.0 | 19.9 | 0.00 | 21.1 | 21.2 | 0.00 |
| 75-79 | 20.3 | 20.9 | -0.02 | 20.4 | 20.4 | 0.00 |
| 80-84 | 19.3 | 18.6 | 0.02 | 18.2 | 18.0 | 0.01 |
| 85-89 | 16.2 | 17.5 | -0.03 | 15.2 | 15.7 | -0.02 |
| 90-94 | 0.8 | 0.8 | 0.00 | 0.7 | 0.5 | 0.02 |
| Medical history: General |  |  |  |  |  |  |
| Acute respiratory disease | 18.9 | 21.2 | -0.06 | 17.0 | 17.2 | 0.00 |
| Attention deficit hyperactivity disorder | 0.2 | 0.2 | -0.01 | 0.3 | 0.2 | 0.02 |
| Chronic liver disease | 2.6 | 2.6 | 0.00 | 2.8 | 2.6 | 0.01 |
| Chronic obstructive lung disease | 15.4 | 16.5 | -0.03 | 13.5 | 12.4 | 0.03 |
| Crohn's disease | 0.4 | 0.3 | 0.02 | 0.3 | 0.2 | 0.01 |
| Dementia | 3.8 | 4.4 | -0.03 | 3.4 | 3.2 | 0.01 |
| Depressive disorder | 11.5 | 12.6 | -0.03 | 10.6 | 10.7 | 0.00 |
| Diabetes mellitus | 30.8 | 34.6 | -0.08 | 31.0 | 30.0 | 0.02 |
| Gastroesophageal reflux disease | 11.6 | 13.6 | -0.06 | 10.8 | 12.0 | -0.04 |
| Gastrointestinal hemorrhage | 5.1 | 5.8 | -0.03 | 4.2 | 4.2 | 0.00 |
| Human immunodeficiency virus infection | 0.3 | 0.3 | 0.00 | 0.3 | 0.3 | 0.00 |
| Hyperlipidemia | 61.9 | 64.7 | -0.06 | 61.0 | 61.9 | -0.02 |
| Hypertensive disorder | 72.9 | 75.1 | -0.05 | 72.0 | 70.8 | 0.03 |
| Lesion of liver | 4.0 | 5.0 | -0.04 | 3.8 | 4.5 | -0.03 |
| Obesity | 10.3 | 12.3 | -0.06 | 10.8 | 10.9 | 0.00 |
| Osteoarthritis | 39.1 | 39.8 | -0.01 | 37.3 | 37.8 | -0.01 |
| Pneumonia | 7.4 | 9.5 | -0.07 | 5.9 | 5.9 | 0.00 |
| Psoriasis | 1.1 | 1.0 | 0.01 | 1.1 | 1.0 | 0.01 |
| Renal impairment | 27.6 | 30.0 | -0.05 | 25.1 | 23.7 | 0.03 |
| Rheumatoid arthritis | 1.0 | 1.0 | 0.00 | 0.9 | 0.9 | 0.00 |
| Schizophrenia | -0.1 | -0.1 | 0.01 | -0.2 | -0.2 | 0.01 |
| Ulcerative colitis | 0.5 | 0.6 | 0.00 | 0.6 | 0.4 | 0.04 |
| Urinary tract infectious disease | 20.4 | 22.9 | -0.06 | 18.3 | 17.8 | 0.01 |
| Viral hepatitis C | 0.6 | 0.6 | 0.00 | 0.5 | 0.5 | 0.01 |
| Visual system disorder | 45.5 | 47.1 | -0.03 | 45.5 | 46.2 | -0.01 |
| Medical history: Cardiovascular disease |  |  |  |  |  |  |
| Atrial fibrillation | 15.5 | 16.5 | -0.03 | 11.4 | 11.2 | 0.00 |
| Cerebrovascular disease | 7.4 | 8.0 | -0.02 | 6.3 | 6.7 | -0.02 |
| Coronary arteriosclerosis | 28.4 | 29.0 | -0.01 | 23.6 | 22.8 | 0.02 |
| Heart disease | 50.9 | 52.7 | -0.04 | 45.6 | 44.7 | 0.02 |
| Heart failure | 13.3 | 16.3 | -0.08 | 6.5 | 6.1 | 0.02 |
| Ischemic heart disease | 13.2 | 14.0 | -0.02 | 10.2 | 9.1 | 0.04 |
| Peripheral vascular disease | 36.0 | 36.9 | -0.02 | 32.6 | 32.4 | 0.00 |
| Pulmonary embolism | 2.7 | 2.9 | -0.01 | 1.9 | 2.0 | -0.01 |
| Venous thrombosis | 5.2 | 5.6 | -0.02 | 4.3 | 4.6 | -0.02 |
| Medical history: Neoplasms |  |  |  |  |  |  |
| Hematologic neoplasm | 20.3 | 20.7 | -0.01 | 19.2 | 20.1 | -0.02 |
| Malignant lymphoma | 1.7 | 1.7 | 0.00 | 1.7 | 1.6 | 0.01 |
| Malignant neoplasm of anorectum | 0.9 | 0.8 | 0.01 | 0.9 | 0.8 | 0.01 |
| Malignant neoplastic disease | 99.8 | 99.9 | -0.02 | 99.7 | 99.9 | -0.04 |
| Malignant tumor of breast | 0.5 | 0.6 | -0.01 | 0.6 | 0.5 | 0.01 |
| Malignant tumor of colon | 2.5 | 2.4 | 0.00 | 2.3 | 1.8 | 0.04 |
| Malignant tumor of lung | 5.5 | 5.0 | 0.02 | 5.1 | 4.6 | 0.02 |
| Malignant tumor of urinary bladder | 5.3 | 5.4 | 0.00 | 4.7 | 4.8 | 0.00 |
| Primary malignant neoplasm of prostate | 99.8 | 99.9 | -0.02 | 99.7 | 99.9 | -0.04 |
| Medication use |  |  |  |  |  |  |
| Agents acting on the renin-angiotensin system | 48.6 | 50.6 | -0.04 | 48.8 | 48.4 | 0.01 |
| Antibacterials for systemic use | 65.5 | 66.3 | -0.02 | 62.4 | 62.3 | 0.00 |
| Antidepressants | 21.3 | 22.7 | -0.03 | 20.6 | 20.7 | 0.00 |
| Antiepileptics | 16.3 | 16.7 | -0.01 | 15.6 | 15.0 | 0.02 |
| Antiinflammatory and antirheumatic products | 21.6 | 21.8 | -0.01 | 20.8 | 21.8 | -0.02 |
| Antineoplastic agents | 14.2 | 17.0 | -0.08 | 15.5 | 15.0 | 0.01 |
| Antipsoriatics | 1.1 | 1.2 | -0.01 | 0.7 | 0.9 | -0.02 |
| Antithrombotic agents | 29.1 | 28.7 | 0.01 | 24.3 | 23.1 | 0.03 |
| Beta blocking agents | 39.1 | 39.7 | -0.01 | 35.2 | 33.8 | 0.03 |
| Calcium channel blockers | 27.2 | 29.8 | -0.06 | 27.3 | 27.4 | 0.00 |
| Diuretics | 38.0 | 41.6 | -0.07 | 35.7 | 35.0 | 0.01 |
| Drugs for acid related disorders | 30.5 | 33.6 | -0.07 | 28.7 | 29.5 | -0.02 |
| Drugs for obstructive airway diseases | 21.2 | 22.7 | -0.04 | 19.6 | 20.1 | -0.01 |
| Drugs used in diabetes | 21.7 | 26.1 | -0.10 | 22.1 | 22.1 | 0.00 |
| Immunosuppressants | 1.5 | 1.6 | -0.01 | 1.8 | 1.4 | 0.03 |
| Lipid modifying agents | 52.8 | 54.1 | -0.03 | 51.8 | 51.8 | 0.00 |
| Opioids | 43.6 | 43.6 | 0.00 | 41.6 | 39.3 | 0.05 |
| Psycholeptics | 33.6 | 34.4 | -0.02 | 32.6 | 31.7 | 0.02 |
| Psychostimulants, agents used for adhd and nootropics | 1.5 | 1.5 | 0.00 | 1.6 | 1.2 | 0.03 |

## Optum (keep all) / 1:100 variable ratio matching

### Users of abiraterone + prednisone with CRPC vs. Users of enzalutamide with CRPC

### Acute myocardial infarction

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Before matching |  | | After matching |  | |
|  | of abiraterone + prednisone with CRPC | Users of enzalutamide with CRPC |  | of abiraterone + prednisone with CRPC | Users of enzalutamide with CRPC |  |
| Characteristic | % | % | Std. diff | % | % | Std. diff |
| Age group |  |  |  |  |  |  |
| 45-49 | 0.3 | 0.2 | 0.01 | -0.2 | 0.3 | -0.03 |
| 50-54 | 1.1 | 0.8 | 0.03 | 1.0 | 0.9 | 0.01 |
| 55-59 | 3.6 | 2.7 | 0.05 | 3.9 | 2.7 | 0.07 |
| 60-64 | 6.8 | 6.5 | 0.01 | 7.1 | 6.5 | 0.02 |
| 65-69 | 11.5 | 12.0 | -0.01 | 11.2 | 12.8 | -0.05 |
| 70-74 | 20.0 | 19.9 | 0.00 | 21.4 | 20.9 | 0.01 |
| 75-79 | 20.3 | 20.9 | -0.02 | 20.5 | 20.8 | -0.01 |
| 80-84 | 19.3 | 18.6 | 0.02 | 18.1 | 17.8 | 0.01 |
| 85-89 | 16.2 | 17.5 | -0.03 | 15.7 | 16.5 | -0.02 |
| 90-94 | 0.8 | 0.8 | 0.00 | 0.9 | 0.5 | 0.06 |
| Medical history: General |  |  |  |  |  |  |
| Acute respiratory disease | 18.9 | 21.2 | -0.06 | 19.1 | 19.0 | 0.00 |
| Attention deficit hyperactivity disorder | 0.2 | 0.2 | -0.01 | 0.2 | -0.1 | 0.01 |
| Chronic liver disease | 2.6 | 2.6 | 0.00 | 2.7 | 2.7 | 0.00 |
| Chronic obstructive lung disease | 15.4 | 16.5 | -0.03 | 15.3 | 15.0 | 0.01 |
| Crohn's disease | 0.4 | 0.3 | 0.02 | 0.3 | 0.2 | 0.01 |
| Dementia | 3.8 | 4.4 | -0.03 | 3.5 | 3.6 | -0.01 |
| Depressive disorder | 11.5 | 12.6 | -0.03 | 11.2 | 11.5 | -0.01 |
| Diabetes mellitus | 30.8 | 34.6 | -0.08 | 32.8 | 30.9 | 0.04 |
| Gastroesophageal reflux disease | 11.6 | 13.6 | -0.06 | 11.7 | 12.4 | -0.02 |
| Gastrointestinal hemorrhage | 5.1 | 5.8 | -0.03 | 4.6 | 4.6 | 0.00 |
| Human immunodeficiency virus infection | 0.3 | 0.3 | 0.00 | 0.3 | 0.3 | 0.00 |
| Hyperlipidemia | 61.9 | 64.7 | -0.06 | 61.0 | 62.9 | -0.04 |
| Hypertensive disorder | 72.9 | 75.1 | -0.05 | 72.4 | 72.2 | 0.00 |
| Lesion of liver | 4.0 | 5.0 | -0.04 | 3.9 | 4.5 | -0.03 |
| Obesity | 10.3 | 12.3 | -0.06 | 11.3 | 11.7 | -0.01 |
| Osteoarthritis | 39.1 | 39.8 | -0.01 | 38.0 | 38.8 | -0.02 |
| Pneumonia | 7.4 | 9.5 | -0.07 | 7.4 | 7.7 | -0.01 |
| Psoriasis | 1.1 | 1.0 | 0.01 | 1.2 | 1.0 | 0.01 |
| Renal impairment | 27.6 | 30.0 | -0.05 | 27.7 | 26.3 | 0.03 |
| Rheumatoid arthritis | 1.0 | 1.0 | 0.00 | 1.1 | 1.0 | 0.01 |
| Schizophrenia | -0.1 | -0.1 | 0.01 | -0.2 | -0.1 | 0.01 |
| Ulcerative colitis | 0.5 | 0.6 | 0.00 | 0.6 | 0.4 | 0.02 |
| Urinary tract infectious disease | 20.4 | 22.9 | -0.06 | 19.8 | 19.2 | 0.01 |
| Viral hepatitis C | 0.6 | 0.6 | 0.00 | 0.6 | 0.5 | 0.00 |
| Visual system disorder | 45.5 | 47.1 | -0.03 | 46.1 | 46.8 | -0.01 |
| Medical history: Cardiovascular disease |  |  |  |  |  |  |
| Atrial fibrillation | 15.5 | 16.5 | -0.03 | 14.5 | 14.3 | 0.00 |
| Cerebrovascular disease | 7.4 | 8.0 | -0.02 | 6.6 | 7.2 | -0.02 |
| Coronary arteriosclerosis | 28.4 | 29.0 | -0.01 | 25.7 | 25.2 | 0.01 |
| Heart disease | 50.9 | 52.7 | -0.04 | 49.1 | 48.6 | 0.01 |
| Heart failure | 13.3 | 16.3 | -0.08 | 12.6 | 12.5 | 0.00 |
| Ischemic heart disease | 13.2 | 14.0 | -0.02 | 10.2 | 10.4 | -0.01 |
| Peripheral vascular disease | 36.0 | 36.9 | -0.02 | 34.5 | 34.5 | 0.00 |
| Pulmonary embolism | 2.7 | 2.9 | -0.01 | 2.5 | 2.2 | 0.02 |
| Venous thrombosis | 5.2 | 5.6 | -0.02 | 4.8 | 4.8 | 0.00 |
| Medical history: Neoplasms |  |  |  |  |  |  |
| Hematologic neoplasm | 20.3 | 20.7 | -0.01 | 19.4 | 20.5 | -0.03 |
| Malignant lymphoma | 1.7 | 1.7 | 0.00 | 1.7 | 1.7 | 0.00 |
| Malignant neoplasm of anorectum | 0.9 | 0.8 | 0.01 | 0.9 | 0.8 | 0.00 |
| Malignant neoplastic disease | 99.8 | 99.9 | -0.02 | 99.8 | 99.9 | -0.04 |
| Malignant tumor of breast | 0.5 | 0.6 | -0.01 | 0.6 | 0.5 | 0.01 |
| Malignant tumor of colon | 2.5 | 2.4 | 0.00 | 2.5 | 2.0 | 0.04 |
| Malignant tumor of lung | 5.5 | 5.0 | 0.02 | 5.4 | 4.5 | 0.04 |
| Malignant tumor of urinary bladder | 5.3 | 5.4 | 0.00 | 5.6 | 4.8 | 0.04 |
| Primary malignant neoplasm of prostate | 99.8 | 99.9 | -0.02 | 99.8 | 99.9 | -0.04 |
| Medication use |  |  |  |  |  |  |
| Agents acting on the renin-angiotensin system | 48.6 | 50.6 | -0.04 | 49.3 | 49.2 | 0.00 |
| Antibacterials for systemic use | 65.5 | 66.3 | -0.02 | 63.9 | 63.7 | 0.00 |
| Antidepressants | 21.3 | 22.7 | -0.03 | 21.5 | 21.4 | 0.00 |
| Antiepileptics | 16.3 | 16.7 | -0.01 | 16.1 | 15.6 | 0.01 |
| Antiinflammatory and antirheumatic products | 21.6 | 21.8 | -0.01 | 20.8 | 21.7 | -0.02 |
| Antineoplastic agents | 14.2 | 17.0 | -0.08 | 15.7 | 15.4 | 0.01 |
| Antipsoriatics | 1.1 | 1.2 | -0.01 | 1.2 | 0.9 | 0.03 |
| Antithrombotic agents | 29.1 | 28.7 | 0.01 | 26.8 | 25.3 | 0.04 |
| Beta blocking agents | 39.1 | 39.7 | -0.01 | 37.2 | 36.7 | 0.01 |
| Calcium channel blockers | 27.2 | 29.8 | -0.06 | 27.3 | 28.1 | -0.02 |
| Diuretics | 38.0 | 41.6 | -0.07 | 38.6 | 38.7 | 0.00 |
| Drugs for acid related disorders | 30.5 | 33.6 | -0.07 | 29.9 | 30.4 | -0.01 |
| Drugs for obstructive airway diseases | 21.2 | 22.7 | -0.04 | 21.1 | 22.0 | -0.02 |
| Drugs used in diabetes | 21.7 | 26.1 | -0.10 | 23.6 | 22.8 | 0.02 |
| Immunosuppressants | 1.5 | 1.6 | -0.01 | 1.9 | 1.5 | 0.03 |
| Lipid modifying agents | 52.8 | 54.1 | -0.03 | 52.1 | 52.5 | -0.01 |
| Opioids | 43.6 | 43.6 | 0.00 | 42.7 | 40.8 | 0.04 |
| Psycholeptics | 33.6 | 34.4 | -0.02 | 33.5 | 32.7 | 0.02 |
| Psychostimulants, agents used for adhd and nootropics | 1.5 | 1.5 | 0.00 | 1.6 | 1.2 | 0.03 |